Breaking Finance News

Jefferies downgraded AcelRx (NASDAQ:ACRX) from Buy to Hold in a statement released earlier today.

Jefferies has downgraded AcelRx (NASDAQ:ACRX) from Buy to Hold in a statement released on 10/13/2017.

On Friday July 14, 2017, Jefferies Group LLC released a statement about AcelRx (NASDAQ:ACRX) increased the target price from $0.00 to $7.00 that suggested an upside of 2.07%.

Yesterday AcelRx (NASDAQ:ACRX) traded -59.81% lower at $2.15. The company’s 50-day moving average is $3.80 and its 200-day moving average is $2.97. The last closing price is down -27.73% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the date range. Volume of trade was up over the average, with 24,274,300 shares of ACRX changing hands over the typical 2,214,920

Performance Chart


With a total market value of $0, AcelRx has with a 52 week low of $1.95 and a 52 week high of $5.75 .

A total of 4 brokers have issued a ratings update on the company. 1 brokerage rating the stock a strong buy, 3 firms rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the company a underperform, and finally zero equity analysts rating the company a sell with a 12-month price target of $7.63.

General Company Details For AcelRx (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.